Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) As Induction Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Blood (2022) 140 (Supplement 1): 1702–1704.

https://doi.org/10.1182/blood-2022-167931

Published: 2022

Journal Articles

Genomic Evolution of Patients with Myelodysplastic Syndrome after Hypomethylating Agent Failure

Blood (2022) 140 (Supplement 1): 9773–9775.

https://doi.org/10.1182/blood-2022-169213

Published: 2022

Journal Articles

A Phase I/II Study of Seclidemstat, an LSD1 Inhibitor, and Azacitidine for Patients with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Guillermo Montalban-Bravo, Courtney D. DiNardo, Nicholas Short, Tapan M. Kadia, Farhad Ravandi, Kelly S. Chien, Joby Joseph, Jane Waukau, Sherry A. Pierce, Hagop Kantarjian, Guillermo Garcia-Manero

Blood (2022) 140 (Supplement 1): 9771–9772.

https://doi.org/10.1182/blood-2022-170138

Published: 2022

Journal Articles

Clinical Outcomes and Impact of Therapeutic Intervention in Patients (pts) with Acute Myeloid Leukemia (AML) with Recurrence of Measurable Residual Disease (MRD) after Achievement of MRD-Negative Remission

Blood (2022) 140 (Supplement 1): 543–545.

https://doi.org/10.1182/blood-2022-156955

Published: 2022

Journal Articles

RAS Pathway Mutations Are Associated with Progression after Hypomethylating Agent Therapy in Chronic Myelomonocytic Leukemia

Guillermo Montalban-Bravo, Faezeh Darbaniyan, Kelly S. Chien, Danielle Hammond, Rashmi Kanagal-Shamanna, Tapan M. Kadia, Courtney D. DiNardo, Naval Daver, Farhad Ravandi, Elias Jabbour, Naveen Pemmaraju, Nicholas Short, Koichi Takahashi, Zeev E. Estrov, Sherry A. Pierce, Hagop Kantarjian, Guillermo Garcia-Manero

Blood (2022) 140 (Supplement 1): 4036–4038.

https://doi.org/10.1182/blood-2022-170069

Published: 2022

Journal Articles

Splicing Gene Mutations Do Not Affect Outcomes in Newly Diagnosed Patients with Acute Myeloid Leukemia

Jayastu Senapati, Nicholas Short, Abhishek Maiti, Hussein A Abbas, Naval Daver, Naveen Pemmaraju, Sherry A. Pierce, Kelly S. Chien, Koji Sasaki, Danielle Hammond, Gautam Borthakur, Farhad Ravandi, Hagop Kantarjian, Courtney D. DiNardo

Blood (2022) 140 (Supplement 1): 1427–1429.

https://doi.org/10.1182/blood-2022-169934

Published: 2022

Journal Articles

A Phase II Study of the Sequential Combination of Low-Intensity Chemotherapy (mini-hyper-CVD) and Ponatinib Followed By Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Daniel Nguyen, Elias Jabbour, Nicholas Short, Ghayas C. Issa, Musa Yilmaz, Naval Daver, Naveen Pemmaraju, Kelly S. Chien, Lucia Masarova, Farhad Ravandi, Nitin Jain, Wuliamatu Deen, Min Zhao, Christopher Loiselle, Lourdes Waller, Glenda Banks, Rebecca Garris, Hagop Kantarjian

Blood (2022) 140 (Supplement 1): 6127–6129.

https://doi.org/10.1182/blood-2022-167883

Published: 2022

Journal Articles

Non-Canonical FLT3 Mutations (FLT3m) in Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) - Outcomes and Prognosis after FLT3 Inhibitor (FLT3i) and Venetoclax Based Regimens

Sai Prasad Desikan, Naval Daver, Sanam Loghavi, Tapan M. Kadia, Nicholas Short, Courtney D. DiNardo, Gautam Borthakur, Sherry A. Pierce, Keyur P. Patel, Hussein A Abbas, Abhishek Maiti, Guillermo Garcia-Manero, Farhad Ravandi, Hagop Kantarjian, Musa Yilmaz

Blood (2022) 140 (Supplement 1): 11788–11790.

https://doi.org/10.1182/blood-2022-166655

Published: 2022

Journal Articles

Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3 -Mutated Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 2007–2009.

https://doi.org/10.1182/blood-2022-157210

Published: 2022

Journal Articles

The Adverse Effect of Myelodysplasia-Related Mutations in De Novo Acute Myeloid Leukemia Is Associated with Higher Variant Allelic Frequency (VAF): A Proposal for a Numeric Cutoff for Variant Allelic Frequency

Blood (2022) 140 (Supplement 1): 6306–6308.

https://doi.org/10.1182/blood-2022-164494

Published: 2022

Journal Articles

Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 6170–6172.

https://doi.org/10.1182/blood-2022-164986

Published: 2022

Journal Articles

Long-Term Outcomes of Acute Myeloid Leukemia Following Allogeneic Stem-Cell Transplantation after Decitabine and Venetoclax: Subgroup Analysis of a Phase II Trial

Blood (2022) 140 (Supplement 1): 7725–7728.

https://doi.org/10.1182/blood-2022-169896

Published: 2022

Journal Articles

A Descriptive Analysis of TP53 Y220C Mutations in Patients with Hematologic Malignancies

Georgina Gener-Ricos, Koji Sasaki, Sanam Loghavi, Abhishek Maiti, Nicholas Short, Fadi Haddad, Naval Daver, Gautam Borthakur, Farhad Ravandi, Hagop Kantarjian, Keyur P. Patel, Michael Andreeff, Courtney D. DiNardo

Blood (2022) 140 (Supplement 1): 11830–11832.

https://doi.org/10.1182/blood-2022-167923

Published: 2022

Journal Articles

Del5q with One Additional Cytogenetic Abnormality Other Than Del20q Identifies a Higher Risk Population of MDS Patients

Robert E. Briski, Kelly S. Chien, Guillermo Montalban-Bravo, Tapan M. Kadia, Elias Jabbour, Naveen Pemmaraju, Koji Sasaki, Danielle Hammond, Nicholas Short, Farhad Ravandi, Yesid Alvarado, Sherry A. Pierce, Guillermo Garcia-Manero, Hagop Kantarjian

Blood (2022) 140 (Supplement 1): 4042–4044.

https://doi.org/10.1182/blood-2022-170029

Published: 2022

Journal Articles

Improved Outcomes with Low-Dose Inotuzumab and Mini-Hyper-CVD Followed By Blinatumomab Consolidation in Relapsed-Refractory Acute Lymphoblastic Leukemia: Results of a Phase II Study

Blood (2022) 140 (Supplement 1): 11698–11701.

https://doi.org/10.1182/blood-2022-170049

Published: 2022

Journal Articles

A Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Updated Results and Predictors for Outcomes

Blood (2022) 140 (Supplement 1): 11679–11682.

https://doi.org/10.1182/blood-2022-168052

Published: 2022

Journal Articles

Incorporation of Nelarabine (NEL), Pegylated Asparaginase (PEG) and Venetoclax (VEN) in the Frontline Therapy of Adult Patients with T-Acute Lymphoblastic Leukemia/T-Lymphoblastic Lymphoma (T-ALL/LBL)

Rodrick Babakhanlou, Hagop Kantarjian, Elias Jabbour, Gautam Borthakur, Marina Konopleva, William G. Wierda, Jan A. Burger, Ghayas C. Issa, Abhishek Maiti, Hayley Balkin, Mary Kelly, Rebecca Garris, Alessandra Ferrajoli, Guillermo Garcia-Manero, Yesid Alvarado, Nicholas Short, Nitin Jain, Farhad Ravandi

Blood (2022) 140 (Supplement 1): 11671–11673.

https://doi.org/10.1182/blood-2022-159139

Published: 2022

Journal Articles

Incidence of Central Nervous System Toxicity and Cytokine Release Syndrome in Leukemia Patients Treated with Blinatumomab

Elias Jabbour, Shilpa Paul, Dan E. Nichols, Faezeh Darbaniyan, Jenessa Lee, Koji Sasaki, Nicholas Short, Nitin Jain, Farhad Ravandi, Guillermo Garcia-Manero, Tapan M. Kadia, Guillermo Montalban-Bravo, Gautham Borthakur, Rebecca Garris, Marina Konopleva, Hagop Kantarjian

Blood (2022) 140 (Supplement 1): 11663–11665.

https://doi.org/10.1182/blood-2022-170579

Published: 2022

Journal Articles

Myelodysplastic Syndromes without Detectable Mutations: Analysis of Clinical Presentation and Outcome

Alex Bataller, Rashmi Kanagal-Shamanna, Kelly S. Chien, Guillermo Montalban-Bravo, Tapan M. Kadia, Farhad Ravandi, Courtney D. DiNardo, Naval Daver, Nicholas Short, Gautam Borthakur, Elias Jabbour, Danielle Hammond, Lucia Masarova, Irene Ganan-Gomez, Vera Adema, Hagop Kantarjian, Guillermo Garcia-Manero, Koji Sasaki

Blood (2022) 140 (Supplement 1): 9793–9795.

https://doi.org/10.1182/blood-2022-164962

Published: 2022

Journal Articles

Ponatinib and Blinatumomab for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Subgroup Analysis from a Phase II Study

Blood (2022) 140 (Supplement 1): 513–515.

https://doi.org/10.1182/blood-2022-157775

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) As Induction Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Genomic Evolution of Patients with Myelodysplastic Syndrome after Hypomethylating Agent Failure

A Phase I/II Study of Seclidemstat, an LSD1 Inhibitor, and Azacitidine for Patients with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Clinical Outcomes and Impact of Therapeutic Intervention in Patients (pts) with Acute Myeloid Leukemia (AML) with Recurrence of Measurable Residual Disease (MRD) after Achievement of MRD-Negative Remission

RAS Pathway Mutations Are Associated with Progression after Hypomethylating Agent Therapy in Chronic Myelomonocytic Leukemia

Splicing Gene Mutations Do Not Affect Outcomes in Newly Diagnosed Patients with Acute Myeloid Leukemia

A Phase II Study of the Sequential Combination of Low-Intensity Chemotherapy (mini-hyper-CVD) and Ponatinib Followed By Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Non-Canonical FLT3 Mutations (FLT3m) in Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) - Outcomes and Prognosis after FLT3 Inhibitor (FLT3i) and Venetoclax Based Regimens

Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3 -Mutated Acute Myeloid Leukemia

The Adverse Effect of Myelodysplasia-Related Mutations in De Novo Acute Myeloid Leukemia Is Associated with Higher Variant Allelic Frequency (VAF): A Proposal for a Numeric Cutoff for Variant Allelic Frequency

Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia

Long-Term Outcomes of Acute Myeloid Leukemia Following Allogeneic Stem-Cell Transplantation after Decitabine and Venetoclax: Subgroup Analysis of a Phase II Trial

A Descriptive Analysis of TP53 Y220C Mutations in Patients with Hematologic Malignancies

Del5q with One Additional Cytogenetic Abnormality Other Than Del20q Identifies a Higher Risk Population of MDS Patients

Improved Outcomes with Low-Dose Inotuzumab and Mini-Hyper-CVD Followed By Blinatumomab Consolidation in Relapsed-Refractory Acute Lymphoblastic Leukemia: Results of a Phase II Study

A Phase II Study of Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Updated Results and Predictors for Outcomes

Incorporation of Nelarabine (NEL), Pegylated Asparaginase (PEG) and Venetoclax (VEN) in the Frontline Therapy of Adult Patients with T-Acute Lymphoblastic Leukemia/T-Lymphoblastic Lymphoma (T-ALL/LBL)

Incidence of Central Nervous System Toxicity and Cytokine Release Syndrome in Leukemia Patients Treated with Blinatumomab

Myelodysplastic Syndromes without Detectable Mutations: Analysis of Clinical Presentation and Outcome

Ponatinib and Blinatumomab for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Subgroup Analysis from a Phase II Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only